Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | DTYMK | P23919 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448258 | 0.86 | TDP1 (0.47) | TDP1L3MBTL1CASP6ALDH1A1MAPT | |
| SCHEMBL21749965 | 0.84 | TDP1 (0.51) | TDP1L3MBTL1CASP6ALDH1A1MAPT | |
| SCHEMBL633629 | 0.82 | TDP1 (0.46) | TDP1L3MBTL1CASP6ALDH1A1MAPT | |
| SCHEMBL15727851 | 0.81 | SMN1; SMN2 (0.41) | TDP1ALDH1A1MAPTATMHIF1A | |
| SCHEMBL29154301 | 0.81 | TDP1 (0.45) | TDP1L3MBTL1CASP6ALDH1A1MAPT | |
| SCHEMBL6556043 | 0.81 | DTYMK (0.47) | TDP1L3MBTL1CASP6ALDH1A1MAPT | |
| SCHEMBL1201983 | 0.79 | TDP1 (0.44) | TDP1L3MBTL1CASP6ALDH1A1MAPT | |
| SCHEMBL543983 | 0.79 | TSHR (0.51) | TDP1L3MBTL1CASP6ALDH1A1MAPT | |
| SCHEMBL913380 | 0.79 | TDP1 (0.47) | TDP1L3MBTL1CASP6ALDH1A1MAPT | |
| SCHEMBL29197041 | 0.79 | TDP1 (0.50) | TDP1L3MBTL1CASP6ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) | 2025-04-17 | — | — | US | disclosed |
| CN-119365192-A | Heteroaryl compounds as HPK1 inhibitors and methods of use thereof | 深圳市原力深湾创新药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4463150-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-117062814-A | Compounds that rapidly accelerate fibrosarcoma protein degradation and related methods of use | 阿维纳斯运营公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| EP-4204418-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| CN-101631784-A | Bicyclic lactam factor VIIA inhibitors useful as anticoagulants | BRISTOL MYERS SQUIBB CO | 2010-01-20 | — | — | CN | disclosed |
| EP-2099783-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008079759-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079759-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | TDP1 1696/4885L3MBTL1 989/4885CASP6 3082/4885 |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F8, F9 | TDP1 3824/4885L3MBTL1 2078/4885CASP6 317/4885 |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | CRBN, RBX1, ARAF | TDP1 1620/4885L3MBTL1 1064/4885CASP6 3116/4885 |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | TDP1 1696/4885L3MBTL1 989/4885CASP6 3082/4885 |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SGK1, HYPK, PCK1 | TDP1 1421/4885L3MBTL1 3744/4885CASP6 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.